The Alexander Project 1996-1997: Latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue 2, 2000, Pages 191-203

  Felmingham, David ^a   Grüneberg, Reuben N ^a  

^a GR Micro Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAMASE; CEFACLOR; CEFIXIME; CEFTRIAXONE; CEFUROXIME; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; MACROLIDE; OFLOXACIN; PENICILLIN G; SULFAMETHOXAZOLE; TRIMETHOPRIM;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BRAZIL; COMMUNITY; EUROPEAN UNION; FRANCE; HAEMOPHILUS INFLUENZAE; HONG KONG; HUMAN; HUNGARY; INTERNATIONAL COOPERATION; IRELAND; LOWER RESPIRATORY TRACT INFECTION; MEXICO; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NONHUMAN; PENICILLIN RESISTANCE; PHENOTYPE; PORTUGAL; SAUDI ARABIA; SLOVAKIA; SOUTH AFRICA; SPAIN; STREPTOCOCCUS PNEUMONIA; TH1 CELL; UNITED STATES;

EID: 0011561048     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.2.191     Document Type: Article

References (20)

1. Mandell, L. A. (1995). Community-acquired pneumonia. Etiology, epidemiology and treatment. Chest 108, Suppl., S35-42.
2. Ball, P. (1995). Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108, Suppl., S43-52.
3. Goldstein, F., Bryskier, A. B., Appelbaum, P. C., Bauernfeind, A., Jacobs, M., Schito, G. C. et al. (1998). The etiology of respiratory tract infections and the antibacterial activity of fluoroquinolones and other oral bacterial agents against respiratory pathogens. Clinical Microbiology and Infection 4, Suppl. 2, 2S8-18.
4. Felmingham, D. (1995). Antibiotic resistance. Do we need new therapeutic approaches? Chest 108, Suppl., S70-78.
5. Jones, R. N. (1996). The emergent needs for basic research, education and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antimicrobial Resistance. Diagnostic Microbiology and Infectious Disease 25, 153-61.
6. House of Lords Select Committee on Science and Technology. (1998). Resistance to Antibiotics and Other Antimicrobial Agents. 7th Report. The Stationery Office, London.
7. Felmingham, D. & Grüneberg, R. N. (1996). A multicenter collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993: The Alexander Project. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 1-57.
8. Grüneberg, R. N. & Felmingham, D. (1996). Results of the Alexander Project: a continuing, multicenter study of the antimicrobial susceptibility of community-acquired, lower respiratory tract bacterial pathogens. Diagnostic Microbiology and Infectious Disease 25, 169-81.
9. National Committee for Clinical Laboratory Standards. (1998). Performance Standards for Antimicrobial Susceptibility Testing: Eighth Informational Supplement M100-S8. NCCLS, Wayne, PA.
10. National Committee for Clinical Laboratory Standards. (1995). Performance Standards for Antimicrobial Susceptibility Testing: Sixth Informational Supplement M100-S6. NCCLS, Wayne, PA.
11. Marton, A. (1995). Epidemiology of resistant pneumococci in Hungary. Microbial Drug Resistance 1, 127-30.
12. Felmingham, D. & Washington, J. (1999). Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander Project 1992-1996. Journal of Chemotherapy 11, Suppl. 1, 5-21.
13. Goldstein, F. W. & Acar, J. F. (1996). Antimicrobial resistance among lower respiratory tract isolates of Streptococcus pneumoniae: results of a 1992-1993 western Europe and USA collaborative surveillance study. The Alexander Project Collaborative Group. Journal of Antimicrobial Chemotherapy 38, Suppl. A, 71-84.
14. Goldsmith, C. E., Moore, J. E. & Murphy, P. G. (1997). Pneumococcal resistance in the UK. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 11-8.
15. Doern, G. V., Brueggemann, A., Holley, H. P. & Rauch, A. M. (1996). Antimicrobial resistance of Streptococcus pneumoniae recovered from outpatients in the United States during the winter months of 1994 to 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40, 1208-13.
16. Baquero, F. (1995). Pneumococcal resistance to β-lactam antibiotics: a global geographic overview. Microbial Drug Resistance 1, 115-20.
17. Jacobs, M. R., Bajaksouzian, S., Zilles, A., Lin, G., Pankuch, G. A. & Appelbaum, P. C. (1999). Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US surveillance study. Antimicrobial Agents and Chemotherapy 43, 1901-8.
18. Catlin, B. W. (1990). Branhamella catarrhalis, an organism gaining respect as a pathogen. Clinical Microbiology Reviews 3, 293-320.
19. Jorgensen, J. H., Doern, G. V., Maher, L. A., Howell, A. W. & Redding, J. S. (1990). Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy 34, 2075-80.
20. Doern, G. V., Bruggemann, A. B., Pierce, G., Hogan, T., Holley, H. P. & Rauch, A. (1996). Prevalence of antimicrobial resistance among 723 outpatient clinical isolates of Moraxella catarrhalis in the United States in 1994 and 1995: results of a 30-center national surveillance study. Antimicrobial Agents and Chemotherapy 40, 2884-6.